A Multi – Center Study Of PET Imaging With [F-18] FLT & [F-18] FDG in Cancer Patients for Treatment Evaluation

Inclusion Criteria:

Patient provides written Informed Consent and is willing to comply with protocol requirements
Patient is at least 18 years of age on the day of dosing (male or female of any race or ethnicity)
Patient is capable of lying still in the PET scanner for the protocol required time frame(s)
Patient has a diagnosis of one of the following malignancies using the TNM Staging System:
Lung cancer (T3 grade up, node positive, but no metastatic disease)
Head and neck cancer (T3 grade up, node positive, but no metastatic disease)
Patient has undergone a comparative, diagnostic procedure with lesion(s) visible, other than ultrasound, that includes, but is not limited to computed tomography (CT), magnetic resonance imaging (MRI), nuclear medicine imaging, endoscopy, laparoscopy, standard abdominal x-ray, biopsy and/or surgery for one of the above mentioned areas
Patient is scheduled to start radiotherapy or a chemoradiotherapy regimen for curative intent
As a part of his/her standard radiotherapy or chemoradiotherapy regimen, patient is scheduled to have clinical [F-18]FDG PET scans pre treatment and post treatment (at about 4 weeks (±1 week) after the start of therapy)
Patient is scheduled to have the investigational, pre treatment [F-18] FLT PET scan recommended to be within ± 2 days of the clinical, pre treatment [F-18] FDG PET scan
Patient has not received or intends to receive 5-fluorouracil (chemotherapeutic agent)
Patient has a score of greater than or equal to (>/=) 60% on the Karnofsky Performance Status Scale

Exclusion Criteria:

Patient is a pregnant or lactating female. Exclude the possibility of pregnancy:
by testing on site at the institution (serum or urine βHCG) within 48 hours prior to the start of each investigational product administration
by surgical history (eg, tubal ligation or hysterectomy)
by patient's history of being post menopausal with a minimum 1 year without menses
Patient is undergoing treatment with palliative intent
Patient has received an investigational compound and/or medical device within 14 days before admission into this study
Patient has any medical condition or other circumstances which would significantly decrease the chances of obtaining reliable data, achieving study objectives, or completing the study and/or post-dose follow-up examinations
Patient is determined by the Investigator that he/she is clinically unsuitable for the study.